SCHEMBL30506993

SCHEMBL30506993

CC1(O[Si](C)(C)C(C)(C)C)CC(n2cnc3cccc(C(F)F)c32)C1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KRAS P01116 1/20 0.30
SOS1 Q07889 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26042096 1.00 KRAS (0.30) KRASSOS1
SCHEMBL25315300 1.00 KRAS (0.30) KRASSOS1
SCHEMBL30506769 0.84 PRPS1 (0.30)
SCHEMBL25315918 0.84 PRPS1 (0.30)
SCHEMBL26042063 0.84 PRPS1 (0.30)
SCHEMBL26042097 0.83
SCHEMBL25316417 0.83
SCHEMBL30506849 0.83
SCHEMBL25924497 0.81 KRAS (0.34) KRASSOS1
SCHEMBL25315239 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 WO disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 EP disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed